Skip to main content

Market Overview

ProQR Shares Spiking 40%


ProQR Therapeutics NV (NASDAQ: PRQR) shares rocketed higher in the pre-market session as the company announced its QR-010 Cystic Fibrosis treatment met its primary endpoint during its Phase 1b study.

Following four weeks of treatment, the study showed that QR-010 restored cystic  fibrosis transmembrane conductance regulator function in cystic fibrosis patients.

The company is presenting preliminary data from the Phase 1b study at the North American Cystic Fibrosis Conference today.

Shares of ProQr were higher by $2.40, or 38 percent, to $8.65.


Related Articles (PRQR)

View Comments and Join the Discussion!

Posted-In: Biotech News Movers General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at